arrow
C

Chiara Braconi

royal marsden nhs foundation trust
H指数:43
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers

IDH1 R132突变或HER2阳性与胆道癌对铂类为基础的疗法的获益

2026-05-200
OAAI
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

接受顺铂、吉西他滨和度鲁特韦治疗的胆道癌患者中,转移部位对预后的影响

2026-02-270
PRE
Cholangiocarcinoma 2026: status quo, unmet needs and priorities

胆管癌2026: 现状,未满足的需求和优先事项

2025-12-100
OAAI
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme

英国真实世界证据:通过早期准入方案使用Durvalumab联合顺铂和吉西他滨治疗晚期胆道癌

2025-08-220
PRE
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas

新型铂类衍生物选择性地在原始胆管癌和顺铂耐药胆管癌中引起DNA双链断裂和细胞死亡。

2025-05-030
OAAI
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
ASO Visual Abstract: Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
2024-07-120
PRE
Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease
2024-06-196
OAAI